Abstract
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease in which early diagnosis is often challenging due to atypical clinical manifestations. Laboratory biomarkers such as human leukocyte antigen-B27 (HLA-B27), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) play an essential role in diagnostic evaluation.
Methods: A total of 120 AS patients and 100 healthy controls were enrolled. Venous blood samples were analyzed for HLA-B27 (flow cytometry), ESR (Westergren method), and CRP (immunoturbidimetry). The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was assessed, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
Results: HLA-B27 positivity was significantly higher in the AS group than in controls (92.5% vs. 5.0%, P<0.001). Both ESR and CRP levels were markedly elevated in AS patients and showed a progressive increase with higher BASDAI scores (P<0.05). ROC analysis demonstrated superior diagnostic efficacy of combined HLA-B27, ESR, and CRP detection (AUC=1.000, sensitivity 97.2%, specificity 93.3%) compared with single markers.
Conclusion: The combined detection of HLA-B27, ESR, and CRP provides a reliable laboratory-based diagnostic approach for ankylosing spondylitis, enhancing accuracy and clinical applicability. These findings highlight the importance of integrating biochemical and immunogenetic markers into routine diagnostic practice.
Keywords
Array
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.